Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000950170-25-043406
Filing Date
2025-03-21
Accepted
2025-03-21 18:33:54
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 9715
2 EX-99.1 ck0001669811-ex99_1.pdf EX-99.1 71320
  Complete submission text file 0000950170-25-043406.txt   110062
Mailing Address 1735 BUFORD HIGHWAY STE. 215-113 CUMMING GA 30041
Business Address 1735 BUFORD HIGHWAY STE. 215-113 CUMMING GA 30041 470-514-4013
Vicapsys Life Sciences, Inc. (Subject) CIK: 0001468639 (see all company filings)

EIN.: 621153426 | State of Incorp.: FL | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-85123 | Film No.: 25761863
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 888 SEVENTH AVENUE 37TH FLOOR NEW YORK NY 10106
Business Address 888 SEVENTH AVENUE 37TH FLOOR NEW YORK NY 10106 212-468-5100
Wildcat Capital Management, LLC (Filed by) CIK: 0001582384 (see all company filings)

EIN.: 453715536 | State of Incorp.: DE | Fiscal Year End: 1213
Type: SCHEDULE 13G